Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 17/20 | 0.71 |
| ▸ | IDH2 | P48735 | 5/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102694 | 1.00 | IDH1 (0.71) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL16393370 | 0.93 | IDH1 (0.71) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL15094939 | 0.93 | IDH2 (0.67) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29763422 | 0.93 | IDH2 (0.67) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29660732 | 0.92 | IDH1 (0.79) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL18471368 | 0.90 | IDH1 (0.61) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29660707 | 0.90 | IDH1 (0.70) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL23390820 | 0.88 | IDH1 (0.59) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL29660826 | 0.88 | IDH1 (0.67) | IDH1IDH2ABCB11ADORA3CHRM1 | |
| SCHEMBL23181513 | 0.88 | IDH1 (0.67) | IDH1IDH2ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085059-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2026-03-26 | — | — | US | disclosed |
| CN-111662271-B | Compound with IDH mutant inhibitory activity and preparation method and application thereof | 中国药科大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-116804003-A | Crystal of 1,3, 5-triazine derivative mesylate and preparation method thereof | 正大天晴药业集团股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-110372670-B | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2023-04-07 | — | — | CN | disclosed |
| EP-4147692-A1 | COMBINATION THERAPY FOR TREATING MALIGNANCIES | Les Laboratoires Servier (FR) | 2023-03-15 | — | — | EP | disclosed |
| CN-115536635-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-30 | — | — | CN | disclosed |
| CN-115521264-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-12-27 | — | — | CN | disclosed |
| CN-114933585-A | Therapeutically active compounds and methods of use thereof | 法国施维雅药厂 | 2022-08-23 | — | — | CN | disclosed |
| CN-108601787-B | Combination therapy for the treatment of malignant tumors | 细胞基因公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-3572409-B1 | 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-107641114-B | Compound as isocitrate dehydrogenase inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-108912066-B | Therapeutically active compounds and methods of use thereof | 安吉奥斯医药品有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-109890806-B | Compound as isocitrate dehydrogenase inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-109265444-B | Optical isomer of substituted triazine IDH inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-110051673-B | Pharmaceutical composition containing triazine IDH inhibitor and application thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085059-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH2, IDH3B, IDH1 | IDH1 3/4885IDH2 1/4885ABCB11 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.